LATEST
Tue, Nov 17, 2026
Loading weather...
Markets

Novo Nordisk Highlights Protective Bone Biomarkers For CagriSema And Pediatric BMI Drops

Novo Nordisk AG (NYSE:NVO) presented new data at ObesityWeek 2026 demonstrating that its investigational amylin-based th...

Novo Nordisk AG (NYSE:NVO) presented new data at ObesityWeek 2026 demonstrating that its investigational amylin-based therapies support bone health during weight loss, while once-weekly semaglutide significantly reduces body mass index in children with obesity. Amylin Pipeline Protects Bone Health Substantial weight loss from medication, surgery, or diet can lower bone mass and increase fracture risks. On Tuesday, Novo Nordisk shared...

SOURCE: Benzinga
ORIGINAL REPORT: Click here
DHALLO EDITORIAL STATUS: Aggregated & reviewed
Have feedback on this article?Report error or suggestion

Read More from Markets

Home Depot Taps CFO Richard McPhail to Lead, Narrows Profit Outlook

The Home Depot Inc. (NYSE:HD) stock fell Tuesday after the home improvement reta...

Read Article »

Michael Saylor Compliments Twenty One as Bitcoin Treasury Race Heats Up

Twenty One (NYSE:XXI) bought 154.32 Bitcoin (CRYPTO: BTC) for about $10 million ...

Read Article »

FDA Clears Novartis Drug Cosentyx As Steroid Alternative for Inflammatory Pain Causing Stiff Shoulders

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (...

Read Article »
Return to Front Page

5 minutes. The news that matters.

Get the most important stories of the day, without having to browse hundreds of articles.